AAPL310.66-2.00 (-0.64%) ▼|ABBV254.65-0.11 (-0.04%) ▼|ABT95.84+0.21 (+0.22%) ▲|ACN142.14+5.18 (+3.78%) ▲|ADBE221.54+3.47 (+1.59%) ▲|AMAT554.50-38.29 (-6.46%) ▼|AMD516.11-35.94 (-6.51%) ▼|AMGN368.10+1.66 (+0.45%) ▲|AMT165.25+3.14 (+1.94%) ▲|AMZN245.98+1.82 (+0.75%) ▲|AVGO370.78-3.12 (-0.83%) ▼|AXP349.58-6.45 (-1.81%) ▼|BA231.68-2.86 (-1.22%) ▼|BAC59.86-0.04 (-0.07%) ▼|BKNG181.95+0.92 (+0.51%) ▲|BLK1,009.43-1.78 (-0.18%) ▼|BMY57.97+1.27 (+2.24%) ▲|BNY152.91+2.95 (+1.97%) ▲|BRK-B504.00-2.58 (-0.51%) ▼|C140.77-3.09 (-2.15%) ▼|CAT940.12-29.80 (-3.07%) ▼|CL95.03+1.64 (+1.76%) ▲|CMCSA23.41+0.03 (+0.13%) ▲|COF202.89-3.61 (-1.75%) ▼|COP108.44+4.86 (+4.69%) ▲|COST947.50-2.75 (-0.29%) ▼|CRM169.52+3.87 (+2.34%) ▲|CSCO111.79-2.19 (-1.92%) ▼|CVS104.33+2.25 (+2.20%) ▲|CVX174.01+5.91 (+3.52%) ▲|DE603.61-31.63 (-4.98%) ▼|DHR194.19+0.57 (+0.29%) ▲|DIS97.48+0.07 (+0.07%) ▲|DUK128.22+2.25 (+1.79%) ▲|EMR137.91-3.65 (-2.58%) ▼|FDX312.88+2.95 (+0.95%) ▲|GD374.64-2.24 (-0.59%) ▼|GE366.98-11.70 (-3.09%) ▼|GEV1,077.08-74.96 (-6.51%) ▼|GILD136.36+6.75 (+5.21%) ▲|GM76.03-1.82 (-2.34%) ▼|GOOG363.62-1.28 (-0.35%) ▼|GOOGL367.03+0.57 (+0.16%) ▲|GS1,042.98-12.31 (-1.17%) ▼|HD345.21-5.44 (-1.55%) ▼|HON225.05-6.13 (-2.65%) ▼|IBM306.13+6.61 (+2.21%) ▲|INTC110.39-11.81 (-9.66%) ▼|INTU281.17+9.03 (+3.32%) ▲|ISRG427.30-5.53 (-1.28%) ▼|JNJ267.24+7.91 (+3.05%) ▲|JPM339.22+1.50 (+0.44%) ▲|KO84.05+1.09 (+1.31%) ▲|LIN538.23-2.29 (-0.42%) ▼|LLY1,235.56+35.50 (+2.96%) ▲|LMT535.38-2.62 (-0.49%) ▼|LOW220.90-2.88 (-1.29%) ▼|LRCX326.13-24.07 (-6.87%) ▼|MA531.62-1.48 (-0.28%) ▼|MCD282.21+2.71 (+0.97%) ▲|MDLZ60.22+1.05 (+1.77%) ▲|MDT83.83+0.77 (+0.93%) ▲|META615.58+15.29 (+2.55%) ▲|MMM158.01-1.14 (-0.72%) ▼|MO72.96+1.08 (+1.50%) ▲|MRK128.86+2.08 (+1.64%) ▲|MS222.04-0.06 (-0.03%) ▼|MSFT388.84+2.10 (+0.54%) ▲|MU938.38-46.37 (-4.71%) ▼|NEE88.47+1.03 (+1.18%) ▲|NFLX76.18+0.16 (+0.21%) ▲|NKE43.21-0.13 (-0.30%) ▼|NOW110.73+2.80 (+2.59%) ▲|NVDA196.93+1.38 (+0.71%) ▲|ORCL141.60-2.16 (-1.50%) ▼|PEP144.98+1.69 (+1.18%) ▲|PFE24.07+0.35 (+1.48%) ▲|PG152.75+3.44 (+2.30%) ▲|PLTR134.37+1.83 (+1.38%) ▲|PM187.79+3.03 (+1.64%) ▲|QCOM182.97-3.51 (-1.88%) ▼|RTX200.85-0.52 (-0.26%) ▼|SBUX103.61+1.50 (+1.47%) ▲|SCHW101.93+1.31 (+1.30%) ▲|SO97.29+1.30 (+1.35%) ▲|SPG227.19+2.19 (+0.97%) ▲|T21.09+0.51 (+2.48%) ▲|TMO516.62-0.98 (-0.19%) ▼|TMUS184.73+2.94 (+1.62%) ▲|TSLA402.90-16.87 (-4.02%) ▼|TXN293.30-10.20 (-3.36%) ▼|UBER74.33+1.91 (+2.64%) ▲|UNH428.19+10.20 (+2.44%) ▲|UNP283.12+0.53 (+0.19%) ▲|UPS111.96+1.94 (+1.76%) ▲|USB62.89+0.06 (+0.10%) ▲|V352.20-5.05 (-1.41%) ▼|VZ42.59+0.52 (+1.24%) ▲|WFC87.18-0.27 (-0.31%) ▼|WMT111.54+0.89 (+0.80%) ▲|XOM141.69+5.25 (+3.85%) ▲|AAPL310.66-2.00 (-0.64%) ▼|ABBV254.65-0.11 (-0.04%) ▼|ABT95.84+0.21 (+0.22%) ▲|ACN142.14+5.18 (+3.78%) ▲|ADBE221.54+3.47 (+1.59%) ▲|AMAT554.50-38.29 (-6.46%) ▼|AMD516.11-35.94 (-6.51%) ▼|AMGN368.10+1.66 (+0.45%) ▲|AMT165.25+3.14 (+1.94%) ▲|AMZN245.98+1.82 (+0.75%) ▲|AVGO370.78-3.12 (-0.83%) ▼|AXP349.58-6.45 (-1.81%) ▼|BA231.68-2.86 (-1.22%) ▼|BAC59.86-0.04 (-0.07%) ▼|BKNG181.95+0.92 (+0.51%) ▲|BLK1,009.43-1.78 (-0.18%) ▼|BMY57.97+1.27 (+2.24%) ▲|BNY152.91+2.95 (+1.97%) ▲|BRK-B504.00-2.58 (-0.51%) ▼|C140.77-3.09 (-2.15%) ▼|CAT940.12-29.80 (-3.07%) ▼|CL95.03+1.64 (+1.76%) ▲|CMCSA23.41+0.03 (+0.13%) ▲|COF202.89-3.61 (-1.75%) ▼|COP108.44+4.86 (+4.69%) ▲|COST947.50-2.75 (-0.29%) ▼|CRM169.52+3.87 (+2.34%) ▲|CSCO111.79-2.19 (-1.92%) ▼|CVS104.33+2.25 (+2.20%) ▲|CVX174.01+5.91 (+3.52%) ▲|DE603.61-31.63 (-4.98%) ▼|DHR194.19+0.57 (+0.29%) ▲|DIS97.48+0.07 (+0.07%) ▲|DUK128.22+2.25 (+1.79%) ▲|EMR137.91-3.65 (-2.58%) ▼|FDX312.88+2.95 (+0.95%) ▲|GD374.64-2.24 (-0.59%) ▼|GE366.98-11.70 (-3.09%) ▼|GEV1,077.08-74.96 (-6.51%) ▼|GILD136.36+6.75 (+5.21%) ▲|GM76.03-1.82 (-2.34%) ▼|GOOG363.62-1.28 (-0.35%) ▼|GOOGL367.03+0.57 (+0.16%) ▲|GS1,042.98-12.31 (-1.17%) ▼|HD345.21-5.44 (-1.55%) ▼|HON225.05-6.13 (-2.65%) ▼|IBM306.13+6.61 (+2.21%) ▲|INTC110.39-11.81 (-9.66%) ▼|INTU281.17+9.03 (+3.32%) ▲|ISRG427.30-5.53 (-1.28%) ▼|JNJ267.24+7.91 (+3.05%) ▲|JPM339.22+1.50 (+0.44%) ▲|KO84.05+1.09 (+1.31%) ▲|LIN538.23-2.29 (-0.42%) ▼|LLY1,235.56+35.50 (+2.96%) ▲|LMT535.38-2.62 (-0.49%) ▼|LOW220.90-2.88 (-1.29%) ▼|LRCX326.13-24.07 (-6.87%) ▼|MA531.62-1.48 (-0.28%) ▼|MCD282.21+2.71 (+0.97%) ▲|MDLZ60.22+1.05 (+1.77%) ▲|MDT83.83+0.77 (+0.93%) ▲|META615.58+15.29 (+2.55%) ▲|MMM158.01-1.14 (-0.72%) ▼|MO72.96+1.08 (+1.50%) ▲|MRK128.86+2.08 (+1.64%) ▲|MS222.04-0.06 (-0.03%) ▼|MSFT388.84+2.10 (+0.54%) ▲|MU938.38-46.37 (-4.71%) ▼|NEE88.47+1.03 (+1.18%) ▲|NFLX76.18+0.16 (+0.21%) ▲|NKE43.21-0.13 (-0.30%) ▼|NOW110.73+2.80 (+2.59%) ▲|NVDA196.93+1.38 (+0.71%) ▲|ORCL141.60-2.16 (-1.50%) ▼|PEP144.98+1.69 (+1.18%) ▲|PFE24.07+0.35 (+1.48%) ▲|PG152.75+3.44 (+2.30%) ▲|PLTR134.37+1.83 (+1.38%) ▲|PM187.79+3.03 (+1.64%) ▲|QCOM182.97-3.51 (-1.88%) ▼|RTX200.85-0.52 (-0.26%) ▼|SBUX103.61+1.50 (+1.47%) ▲|SCHW101.93+1.31 (+1.30%) ▲|SO97.29+1.30 (+1.35%) ▲|SPG227.19+2.19 (+0.97%) ▲|T21.09+0.51 (+2.48%) ▲|TMO516.62-0.98 (-0.19%) ▼|TMUS184.73+2.94 (+1.62%) ▲|TSLA402.90-16.87 (-4.02%) ▼|TXN293.30-10.20 (-3.36%) ▼|UBER74.33+1.91 (+2.64%) ▲|UNH428.19+10.20 (+2.44%) ▲|UNP283.12+0.53 (+0.19%) ▲|UPS111.96+1.94 (+1.76%) ▲|USB62.89+0.06 (+0.10%) ▲|V352.20-5.05 (-1.41%) ▼|VZ42.59+0.52 (+1.24%) ▲|WFC87.18-0.27 (-0.31%) ▼|WMT111.54+0.89 (+0.80%) ▲|XOM141.69+5.25 (+3.85%) ▲|
20.1 C
New York
Wednesday, July 8, 2026

Tag: development

newssourceFORcompanyinformationcontent1releasesmarket

Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections

Allschwil, Switzerland, July 29, 2025

Amundi: First half and second quarter 2025 results

Amundi: First half and second quarter 2025 results

Questerre announces definitive agreement to acquire 100% of PX Energy

THIS NEWS RELEASE IS NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OF AMERICA TO UNITED STATES NEWSWIRE SERVICES OR UNITED STATES PERSONS

Game On! Tencent Cloud’s EdgeOne Hackathon Is Here

Nearly US$20,000 Prize Pool and 100 Exclusive Rewards for Top Developers Participants use Tencent Cloud EdgeOne to develop games; finalists to showdown for a 24-hour hackathon...

QCI Announces Acquisition of VizExplorer, Establishes Itself as A Data Activation Powerhouse and Fuels Growth with Expanded Product Suite

LAS VEGAS, July 28, 2025 (GLOBE NEWSWIRE) -- Quick Custom Intelligence (QCI) is proud to announce its new status as a powerhouse in the casino and resort data activation world, following a strategic acquisition of VizExplorer and sustained global expansion. Armed with the combined strengths of QCI’s cutting-edge Artificial Intelligence platform and VizExplorer’s renowned analytics intellectual property, the company is uniquely positioned to drive unprecedented growth. This development enables QCI to invest heavily in an expanded product offering, delivering deeper and wider solutions for a gaming industry that is rapidly diversifying in scope and needs.

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.1

New ETC report demonstrates that wind and solar-dominant power systems are competitive, reliable, and technically and economically feasible

LONDON, July 29, 2025 /PRNewswire/ -- The Energy Transitions Commission (ETC) has today published a landmark report, Power Systems Transformation: Delivering Competitive, Resilient Electricity...

New ETC report demonstrates that wind and solar-dominant power systems are competitive, reliable, and technically and economically feasible

LONDON, July 29, 2025 /PRNewswire/ -- The Energy Transitions Commission (ETC) has today published a landmark report, Power Systems Transformation: Delivering Competitive, Resilient Electricity...

Strength Building: How Strength Training Supplements Help You Build Muscle Mass and Keep Growing Stronger – CrazyBulk

New York City, NY, July 28, 2025 (GLOBE NEWSWIRE) -- Build muscle mass and keep growing stronger with CrazyBulk’s legal strength training supplements. Explore the best stacks for real power gains in 2025
In the evolving world of performance fitness, strength building isn’t just about lifting heavier—it’s about training smarter, fueling properly, and choosing science-backed supplements that support sustainable muscle growth. As more athletes, fitness enthusiasts, and bodybuilders shift away from synthetic enhancers, a natural powerhouse is gaining serious ground: CrazyBulk strength training supplements.

Strength Building: How Strength Training Supplements Help You Build Muscle Mass and Keep Growing Stronger – CrazyBulk

New York City, NY, July 28, 2025 (GLOBE NEWSWIRE) -- Build muscle mass and keep growing stronger with CrazyBulk’s legal strength training supplements. Explore the best stacks for real power gains in 2025
In the evolving world of performance fitness, strength building isn’t just about lifting heavier—it’s about training smarter, fueling properly, and choosing science-backed supplements that support sustainable muscle growth. As more athletes, fitness enthusiasts, and bodybuilders shift away from synthetic enhancers, a natural powerhouse is gaining serious ground: CrazyBulk strength training supplements.

Minh Tran, PE, CFM, Joins Quiddity Engineering as Senior Project Manager

AUSTIN, Texas, July 28, 2025 /PRNewswire/ -- Minh Tran, PE, CFM, has joined Quiddity Engineering as a Senior Project Manager in its Central Texas...

H2O America Announces Second Quarter 2025 Financial Results

H2O America reports second quarter 2025 financial results and hosts a live webcast on Tuesday, July 29, 2025 at 2 p.m. (ET).

Vaccines: Mythology, Ideology, and Reality, New Book by John Leake and Peter A. McCullough

NEW YORK, July 28, 2025 /PRNewswire/ -- Vaccines: Mythology, Ideology, and Reality tells the story of immunizations and the celebrated men who developed it with...

Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight

No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDevelopment

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers